Adverum Biotechnologies Inc., of Menlo Park, Calif., appointed Peter Soparkar chief legal officer.
Arctoris Ltd., of Oxford, U.K., appointed John Mattick to its board and Daniel Thomas head of discovery biology.
Aruna Bio Inc., of Athens, Ga., appointed Renee Boerner vice president of regulatory affairs.
Arvelle Therapeutics GmbH, of Zug, Switzerland, appointed Petra Molan senior vice president commercial, effective Nov. 1 and Enrico Dolfini vice president legal counsel, effective Dec. 2.
Assembly Biosciences Inc., of South San Francisco, appointed Luisa Stamm chief medical officer.
Aztherapies Inc., of Boston, appointed Ernest D. Penachio vice president of manufacturing operations and chemistry, manufacturing and controls.
Bavarian Nordic A/S, of Copenhagen, appointed Jean-Christophe May executive vice president and chief commercial officer, effective January 2020.
Biotheryx Inc., of Chappaqua, N.Y., appointed Peter N. Crnkovich to its board.
Entasis Therapeutics Holdings Inc., of Waltham, Mass., appointed David Altarac chief medical officer.
Equillium Inc., of La Jolla, Calif., appointed Bruce Steel president and CEO, effective Jan. 1. Dan Bradbury, its current CEO, will transition to the role of executive chairman of the board. The company also appointed Krishna Polu executive vice president research and development and Christine Zedelmayer senior vice president and chief operating officer, each effective Jan. 1.
Genmab A/S, of Copenhagen, appointed Anthony Pagano executive vice president and chief financial officer, effective March 1, 2020.
Liminal Biosciences Inc., of Laval, Quebec, appointed Moira Daniels head of regulatory affairs and quality assurance.
Neoimmunetech Inc., of Rockville, Md., appointed Rafi Ahmed, David Lebwohl, Crystal L. Mackall and Debasish Roychowdhury to its scientific advisory board.
Neovasc Inc., of Vancouver, British Columbia, appointed Bill Little chief operating officer.
Neurana Pharmaceuticals Inc., of San Diego, appointed Randall Kaye chief medical officer.
Noxopharm Ltd., of Sydney, appointed Alexander Hunter chief commercial officer.
Orion Biotechnology Canada Ltd., of Ottawa, Ontario, appointed Thomas Hecht chairman of its board.
Partner Therapeutics Inc., of Lexington, Mass., appointed John McManus chief business officer.
Precision Biosciences Inc., of Durham, N.C., appointed Kevin J. Buehler to its board.
Rakuten Medical Inc., of San Mateo, Calif., appointed David Chao and Kentaro Hyakuno to its board. It also appointed Brenton Keath chief financial officer and Dana Johnson general counsel and corporate secretary.
Rubryc Therapeutics Inc., of San Carlos, Calif., appointed Rakesh Verma senior vice president, discovery and development.
Valneva SE, of Saint-Herblain, France, appointed Norman W. Baylor and George R. Siber to its scientific advisory board, effective Dec. 1.
Vericel Corp., of Cambridge, Mass., appointed Sean C. Flynn vice president and general counsel.
Verseau Therapeutics Inc., of Bedford, Mass., appointed Tim Smith chief business officer.